Precision Medicine Market Size, Share, By Type (Diagnostics, Therapeutics, and Others), Technology (Bioinformatics, Drug Discovery, Gene Sequencing, Precision Molecular Diagnostics, Big Data Analytics, and Others), Application (Oncology, CNS, Respiratory, Immunology, Hematology, and Others), End-User (Pharmaceutical and Biotechnology Companies, Diagnostic Laboratories, Contract Research Organizations, and Others), and Region - Trends, Analysis, and Forecast till 2035

• Precision Medicine Market size is expected to grow at a valuation of USD 248.1 Billion by 2035.
• The market’s valuation was worth USD 89.3 Billion in 2024.
• Target market is developing at a CAGR of 11.1%.

Precision medicine, also known as customized medicine, is a medical strategy that uses a person's genetic composition, lifestyle, and environment to drive healthcare decisions. It is an innovative technique to treat and prevent disease. The prevalence of chronic diseases, increasing demand for personalized treatments, more government funding, technological advancements, partnerships between pharmaceutical and software companies, growing adoption of targeted therapies, rising healthcare expenditure, rising investments in research and development, developments in the regulatory framework of laboratory tests, and increasing telehealth and remote monitoring of patients is driving the precision medicine market growth. Moreover, precision medicine helps in improving the patient outcomes, reduces costs, and improves healthcare efficiency, thereby, further contributing in the market expansion. 

Impact of AI on Precision Medicine Market:

AI (artificial intelligence) essentially serves as a powerful tool to analyze complex patient data, allowing clinicians to make more informed decisions in precision medicine approaches. Precision medicine and AI work together to provide highly personalized treatment plans by analyzing vast amounts of patient data, including genetic information, to identify specific disease markers and tailor therapies to individual patients. This results in more effective and targeted treatments with potentially improved outcomes and reduced side effects.

Key Drivers of Target Market:

Increasing Collaboration Between Pharmaceutical and Software Companies is Fostering the Market Growth

The precision medicine market is driven largely by the expanding cooperation between software and pharmaceutical companies, which makes it possible to create sophisticated data analysis tools. These tools use artificial intelligence (AI) and machine learning to find possible drug targets, expedite clinical trials, and customize treatment plans based on patient data, all of which eventually result in more efficient and targeted therapies with better patient outcomes.

• For instance, in October 2024, Tempus, a leader in artificial intelligence and precision medicine, announced a collaboration with JW Pharmaceutical, one of the most established pharmaceutical companies in Korea, to leverage both real-world data (RWD) and biological modeling to support efficient hypothesis generation and rapid validation in early therapeutic research in oncology.

Restraints:

Concerns about Data Privacy and Potential Misuse is Obstructing the Market Growth

The utilization of vast amounts of clinical and genomic data in precision medicine raises questions regarding data privacy and possible abuse. Maintaining patient trust, preventing breaches, and ensuring secure storage are all difficult tasks. Additionally, integrating diverse data sources across healthcare systems can be complex. Ethical concerns regarding consent and data sharing further complicate its widespread adoption.

• Counterbalance Statements: To secure patient data, putting strong encryption, stringent access restrictions, and transparent regulatory frameworks into place, and providing stakeholders with ethical data management training may improve compliance and confidence.

Opportunities:

Increasing Patient Care can Unlock Opportunities in the Future

The precision medicine market technologies and therapies is driven by the growing demand for personalized treatment options brought about by increased patient care. This is due to the fact that patients and healthcare providers are realizing the advantages of customizing medical interventions to each patient's unique genetic and biological profile, which can result in better patient outcomes, fewer side effects, and more effective treatments.

• For instance, in January 2025, The Apollo University, in partnership with Apollo Hospitals and the University of Leicester, U.K., inaugurated the Centre for Digital Health and Precision Medicine (CDHPM) at its campus. The initiative aimed to create a global hub for innovative healthcare research, leveraging digital health and precision medicine to transform and increase patient care.

The market is segmented into type, technology, application, end-user, and region.

Type

By type, the market is trifurcated into diagnostic, therapeutics, and others. The therapeutics segment holds the largest precision medicine market share. The segment’s growth is attributed to the substantial developments and expenditures in precision medicine, especially in fields such as cancer, where the usage of tailored therapies such as immune checkpoint inhibitors and monoclonal antibodies is growing.

• For instance, in May 2020, Praxis Precision Medicines, a clinical-stage, genetic neuroscience company, launched with more than USD 100 million in financing since its inception from premier life science investors led by founding investor Blackstone Life Sciences and Novo Holdings, Vida Ventures, Eventide and other prominent funds. Praxis was deploying a precision medicine approach to develop high-impact therapeutics that targeted the underlying causal mechanisms of both prevalent and rare brain disorders with overlapping disease biology.

Technology

Based on technology, the market is divided into bioinformatics, drug discovery, gene sequencing, precision molecular diagnostics, big data analytics, and others. The drug discovery segment is attributed to lead the market as it is essential for developing effective, safe medications for individual patients, and high-throughput screening.

• For instance, in January 2025, Scipher Medicine, announced a strategic partnership to advance rheumatology drug discovery and development by integrating Scipher’s real-world clinical and genomic data insights into Roivant’s research and development efforts. This collaboration would leverage Scipher's unique data and intelligence derived from its PrismRA precision medicine diagnostic.

Application

Under application, the market is classified into oncology, CNS, respiratory, immunology, hematology, and others. The oncology segment is expected to govern the market due to the rising prevalence of cancer and the success of precision oncology therapies. Moreover, precision oncology aims to improve patient outcomes.

• For instance, in December 2024, Aster DM Healthcare, launched three noteworthy initiatives - Precision Oncology Clinics, the Aster Cancer Grid, and Onco Collect by the Dr. Ramesh Nimmegadda Cancer Foundation, marking a significant advancement in India’s cancer treatment landscape. The newly launched initiatives aimed to revolutionize cancer care by offering personalized, data-driven, and research-based treatments, emphasizing genomic approaches to improve patient outcomes.

End-User

On the basis of end user the market is categorized into pharmaceutical and biotechnology companies, diagnostic laboratories, contract research organizations, and others. The pharmaceutical and biotechnology companies segment is projected to influence the market. This is due to the increasing outsourcing of clinical trials by pharmaceutical and biotechnology companies.

• For instance, in January 2023, Personalized therapy simulation and biotechnology company Cellworks announced the launch of two separate business units that would take an in silico approach to testing potential new precision oncology drugs in both pre-clinical and clinical stages. The services, would both accelerate the development of promising therapies in a pharma company’s pipeline and could also be applied to reviving previously studied but unapproved therapy candidates.

End-User

Geographically, the market is branched into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America: This is the region dominating the precision medicine market share by 53.9%. This is due to this region’s large investment in research and development, efficient healthcare system, acceptance of new technologies, high prevalence of chronic diseases, prominent academic and research institutions, and presence of major diagnostic companies.

• For instance, in March 2024, the U.S. Food and Drug Administration approved Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic non-alcoholic steatoBioinformatics (NASH) with moderate to advanced liver scarring (fibrosis), to be used along with diet and exercise. The safety and efficacy of Rezdiffra was evaluated based on an analysis of a surrogate endpoint at month 12 in a 54-month, randomized, double-blind placebo-controlled trial.

Europe: This is the region with the fastest growing CAGR, during the forecast period. This is due to this region’s, significant advancements in biomarker testing, robust healthcare infrastructure, high research and development activity, high healthcare spending, and a large presence of key precision medicine players.  

• For instance, in June 2024, The European Society of Radiology (ESR) announced the launch of a new Thematic Network dedicated to advancing precision medicine for cancer patients in Europe through AI-powered imaging.  The network was launched following a successful proposal submission by the ESR and Cancer Image Europe (EUCAIM) on the EU Health Policy Platform. The bid was one of four successful proposals to establish Thematic Networks with the ESR’s proposal receiving the highest number of votes of all submitted initiatives.

Precision Medicine Market Report Scope:

Segmentation:

By Type:

• Diagnostic
  • Genetic Tests
    • Predictive and Presymptomatic Tests
    • Carrier Testing
    • Prenatal and Newborn Screening
    • Others
  • Biomarker Tests
    • Screening
    • Recurrence Monitoring
    • Therapy Selection
    • Others
• Therapeutics
  • Monoclonal Antibodies
  • Gene Therapy
  • Cell Therapy
  • Others
• Others

By Technology:

• Bioinformatics
• Drug Discovery
• Gene Sequencing
• Precision Molecular Diagnostics
• Big Data Analytics
• Others

By Application:

• Oncology
• CNS (Central Nervous System)
• Respiratory
• Immunology
• Hematology
• Others

By End User:

• Pharmaceutical and Biotechnology Companies
• Diagnostic Laboratories
• Contract Research Organizations
• Others

By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • U.K.
  • France
  • Russia
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • Indonesia
  • Malaysia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of the Middle East & Africa

The companies operating in the precision medicine market are Thermo Fisher Scientific Inc., AstraZeneca, F. Hoffmann-La Roche Ltd, Merck KGaA, Illumina, Inc., and others. The key players are adopting strategies such as using AI and machine learning, investing in data governance, developing personalized treatments, and adopting new technologies for the diversification of the market.

Precision Medicine Market Companies:

• Thermo Fisher Scientific Inc.
• AstraZeneca
• F. Hoffmann-La Roche Ltd
• Merck KGaA
• Illumina, Inc.
• Novartis Pharmaceuticals Corporation
• Bristol-Myers Squibb Company
• GE HealthCare
• Tempus
• Medtronic
• Precision Medicine Group, LLC
• Koninklijke Philips N.V.
• Pfizer Inc.
• Agilent Technologies, Inc.

View a Additional List of Companies in Precision Medicine Market

• In October 2024, The National Institutes of Health (NIH) had launched a proof-of-concept precision medicine clinical trial to test new treatment combinations targeting specific genetic changes in the cancer cells of people with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The trial, funded by NIH's National Cancer Institute (NCI), aimed to accelerate the discovery of more tailored treatments for these aggressive cancers of the blood and bone marrow.
• In October 2024, Ataraxis AI, the leading AI precision medicine company, emerged from stealth with USD 4 million in seed financing co-led by Giant Ventures and Obvious Ventures. The funding, had enabled Ataraxis to develop groundbreaking AI-powered diagnostic tests that significantly enhanced the prediction of patient outcomes and enabled more precise, personalized treatments.

Analyst View:

The precision medicine market is expanding due to a number of factors, including the prevalence of chronic diseases, the growing need for individualized treatments, increased government funding, technological advancements, collaborations between software and pharmaceutical companies, the growing use of targeted therapies, rising healthcare costs, increased R&D investments, changes to the regulations governing laboratory tests, and the rise in telehealth and remote patient monitoring.

More Related Reports

Precision Farming Market
Precision Glass Molding Market
High Precision Digital Pressure Gauges Market
China Precision Medicine Market
Precision Irrigation Market